Nancy E. Lane, M.D.
Rheumatology, Allergy and Clinical Immunology
- Distinguished Professor of Medicine
Genome and Biomedical Sciences Building
451 Health Sciences Dr
Davis, CA 95616
Lawrence J. Ellison Ambulatory Care Center
4860 Y St., Suite 0400
Sacramento, CA 95817
Additional Phone Numbers
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Dr. Lane is an Endowed Professor of Medicine, Rheumatology, and Aging Research; Director for the Center for Musculoskeletal Health; Director of the K12 NIH Building Interdisciplinary Research Careers in Women’s Health (BIRCWH); and principal investigator of the NIH-funded Program on Sex Differences in Musculoskeletal Diseases Across the Lifespan at UC Davis School of Medicine.
Dr. Lane is an internationally recognized scientist in the fields of both osteoporosis and osteoarthritis. Her translational research team has been instrumental in defining the role of glucocorticoids in bone fragility, including their effects on cell stress and vulnerable cell populations including osteocytes.
As a faculty member at UCSF, she pioneered a seminal clinical trial to demonstrate that daily injections of the hormone PTH could reverse glucocorticoid induced osteoporosis. After transitioning to UC Davis, she a developed a novel compound to direct stem cells to the bone to grow new bone and treat osteoporosis. In addition, she has uncovered novel genetic variations that predispose individuals to osteoarthritis, and has studied novel treatments for osteoarthritis.
Dr. Lane organized and directs an NIH-funded junior faculty grant writing workshop that has taught over 300 junior faculty in musculoskeletal medicine grant writing skills that has resulted in a 45% success rate in applicants receiving research grants (2006-present).
As a translational scientist, Dr. Lane has performed pre-clinical, clinical and epidemiological interdisciplinary studies in the field of osteoporosis, osteoarthritis, and women's health. Over the course of 25 years, has mentored over 30 trainees in interdisciplinary research related to musculoskeletal diseases, especially osteoporosis and osteoarthritis. She has co-developed a hybrid compound, LLP2A-Ale, that has shown to be effective in directing mesenchymal stem cells to the bone surface to augment bone formation in young and old rodents, fracture healing and osteonecrosis. She is currently the principal investigator of a California Institute of Regenerative Medicine (CIRM) grant to develop this hybrid compound for clinical use. This hybrid compound may also be applicable to a dental diseases including periodontal disease and to augment bone growth in dental implants.
Dr. Lane’s experience in regenerative medicine, scaling up GMP material, performing preclinical toxicology studies in animal models, and writing a Pre-IND and working with the FDA are appropriate for this planning proposal. Dr. Lane has also performed a randomized double blind placebo controlled study using risedronate for the treatment of moderate to severe periodontal disease, and this experience will also be useful for this planning proposal.
As Site Director at UC Davis for a U24 (C-DOCTOR), Dr. Lane will lead the recruitment of potential ITP teams from UC Davis and will also ensure that the UC Davis Resource Directors are providing the necessary guidance and tools to the Interdisciplinary Translational Project (ITP) teams.
Dr. Lane has been recognized by the university, her medical residents, subspecialty fellows, and by her faculty peers as an outstanding mentor with the UC Davis Dean’s Award for Scientific Mentoring (2008). Her research accomplishments have been recognized by the UC Davis School of Medicine Dean’s Team Science Award (2012), the American College of Rhematology for the Oscar Gluck Memorial Lecture for outstanding work in Osteoporosis (2011), the Remodeling in Bone “RIB Award” by the International Society of Bone and Mineral Research (2012), her election as a Master of the American College of Physicians (2012) and David Trentham Lectureship and Women in Medicine Lectureship at Harvard Medical School (2013). She is also recipient of the Bone and Joint Decade Outstanding Achievement Award for developing a mentoring program in grant writing (2009).
Dr. Lane was president of the board of the United States Bone and Joint Decade (2006-2008), co-led the International Bone and Joint Decade Conference in Washington DC (2010), was elected and serves on the council of the American Society of Bone and Mineral Research (2010-2013), and the Orthopedic Research Society.
Dr. Lane is on the editorial boards of Nature Reviews Rheumatology, Rheumatology (Associate Editor), Seminars in Arthritis and Rheumatism (Associate Editor), co-editor Arthritis and Rheumatism (2005-2010), and Journal of Rheumatology. She was elected to the Association of American Physicians (2006) and the National Academy of Sciences Institute of Medicine (2013), has been named Best Doctors in America annually since 2004, and continues to have an active rheumatology practice.
Rheumatology, Allergy and Clinical Immunology
M.D., UC San Francisco School of Medicine, San Francisco, California, 1980
B.S., UC Davis, Davis, California, 1976
Mount Zion Hospital and Medical Center, San Francisco, California, 1980-83
Palo Alto Veterans Administration Hospital and Stanford University Medical Center, Stanford, California, 1983-85
American Board of Internal Medicine, 1983
American Board of Internal Medicine, Rheumatology, 1986
American Association of Physicians
American College of Rheumatology
American Society of Bone and Mineral Research
National Academy of Medicine (NAM)
Osteoarthritis and Cartilage Research Society International
Select Recent Publications
Lane NE, Corr M. Osteoarthritis in 2016: Anti-NGF treatments for pain – two steps forward, one step back? Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78.
Mohan G, Lay YE, Berka H, Ringwood L, Kot A, Chen H, Yao W, Lane NE. A novel hybrid compound LLP2A-Ale both prevented and rescued the osteoporotic phenotype in a mouse model of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2017 Jan;100(1):67-79.
Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE. Biologic Therapies and Bone Loss in Rheumatoid Arthritis. IOF Chronic Inflammation and Bone Structure (CIBS) Working Group. Osteoporosis Int. 2017 Feb;28(2):429-446.
Lane NE, Shidara K, Wise BL. Osteoarthritis Year in Review 2016: Clinical. Osteoarthritis Cartilage. 2017 Feb;25(2):209-215.
Hiatt RA, Bailer J, Bascom R, Churchill L, Crump K, Foster Riley M, Briedman DB, Gold D, Goldfrank L, Lane NE, Lippmann M, Mittleman M, Needleman P, Phale R, Shin H. Controlled Human Inhalation-Exposure Studies at EPA. Committee on Assessing Toxicologic Risks to Human Subjects Used in Controlled Exposure Studies of Environmental Pollutants. The National Academies of Sciences, Engineering, Medicine. March 2017.
Chang RW, Fitzgerald K, Lane NE, Mikdashi J. Peer Reviewers. Treatment of Osteoarthritis of the Knee: An Update Review. Comparative Effectiveness Review No. 190, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. May 2017.
Lane NE, Corr M, Baer N, Yazici Y. Wnt signaling in osteoarthritis: A 2017 update. Current Treat Options in Rheum, June 2017; (3):101-111.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-1537.Epub 2017 Jun 6. Review. Erratum in: Arthritis Rheumatol. 2017 Nov;69(11):2246.
Katzman WB, Vittinghoff E, Lin F, Schafer A, Long RK, Wong S, Gladin A, Fan B, Allaire B, Kado DM, Lane NE. Targeted spine strengthening exercise and posture training program to reduce hyperkyphosis in older adults: results from the study of hyperkyphosis, exercise, and function (SHEAF) randomized controlled trial. Osteoporos Int. 2017 Oct;28(10):2831-2841.
Stern AR, Yao X, Wang Y, Berhe A, Dallas M, Johnson ML, Yao W, Kimmel DB, Lane NE. Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats. Bone Rep. 2018 Feb 26;8:115-124. eCollection 2018 Jun.